Pro-oncogenic and anti-oncogenic pathways: Opportunities and challenges of cancer therapy

Future Oncology

Volumn 6, Issue 4, 2010, Pages 587-603

  Zhang, Jiao ^a   Chen, Yan Hua ^a   Lu, Qun ^a  

^a EAST CAROLINA UNIVERSITY   (United States)

Author keywords

Cell survival; Integrative cancer therapy; Oncogene; Tumor suppressor

Indexed keywords

BCR ABL PROTEIN; CADHERIN; CATENIN; CISPLATIN; GAMMA SECRETASE; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; NOTCH RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATINUM DERIVATIVE; PROTEIN KINASE B; PROTEIN P53; TRANSCRIPTION FACTOR E2F; TRANSFORMING GROWTH FACTOR;

CANCER DIAGNOSIS; CANCER RISK; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; CARCINOGENESIS; CARCINOGENICITY; CELL GROWTH; CELL PROLIFERATION; CELL TRANSFORMATION; CHRONIC MYELOID LEUKEMIA; DNA SYNTHESIS; DRUG EFFECT; EARLY DIAGNOSIS; GASTROINTESTINAL STROMAL TUMOR; GENE DOSAGE; GENE EXPRESSION; GENE INTERACTION; GENE MUTATION; HUMAN; INTRACELLULAR SIGNALING; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NEOPLASM; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; RETINOBLASTOMA; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; SURVIVAL RATE; SURVIVAL TIME; TESTIS CANCER; TISSUE TYPES; TREATMENT DURATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTO-ONCOGENES; SIGNAL TRANSDUCTION;

EID: 77950617678     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.10.15     Document Type: Review

References (271)

1. Donner L, Turek LP, Ruscetti SK, Fedele LA, Sherr CJ: Transformation-defective mutants of feline sarcoma virus which express a product of the viral Src gene. J. Virol. 35(1), 129-140 (1980).
2. Semczuk A, Postawski K, Przadka D et al.: K-ras gene point mutations and p21ras immunostaining in human ovarian tumors. Eur. J. Gynaecol. Oncol. 25(4), 484-488 (2004).
3. Ni Z, Liu Y, Keshava N et al.: Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos. Mutat. Res. 468(1), 87-92 (2000).
4. Karakosta A, Golias C, Charalabopoulos A et al.: Genetic models of human cancer as a multistep process. Paradigm models of colorectal cancer, breast cancer, and chronic myelogenous and acute lymphoblastic leukaemia. J. Exp. Clin. Cancer Res. 24(4), 505-514 (2005).
5. Leibovitch SA, Leibovitch MP, Guillier M, Hillion J, Harel J: Differential expression of protooncogenes related to transformation and cancer progression in rat myoblasts. Cancer Res. 46(8), 4097-4103 (1986).
6. Radiloff DR, Rinella ES, Threadgill DW: Modeling cancer patient populations in mice: complex genetic and environmental factors. Drug Discov. Today Dis. Models 4(2), 83-88 (2008).
7. Actis AB, Eynard AR: Influence of environmental and nutritional factors on salivary gland tumorigenesis with a special reference to dietary lipids. Eur. J. Clin. Nutr. 54(11), 805-810 (2000).
8. Ehrhardt A, Bartels T, Klocke R, Paul D, Halter R: Increased susceptibility to the tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone in transgenic mice overexpressing c-myc and epidermal growth factor in alveolar type II cells. J. Cancer Res. Clin. Oncol. 129(2), 71-75 (2003).
9. Gatenby RA, Vincent TL: An evolutionary model of carcinogenesis. Cancer Res. 63(19), 6212-6220 (2003).
10. Toren A, Amariglio N, Rechavi G: Curable and non-curable malignancies: lessons from paediatric cancer. Med. Oncol. 13(1), 15-21 (1996).
11. Rich JN, Eyler CE: Cancer stem cells in brain tumor biology. Cold Spring Harb. Symp. Quant. Biol. 73, 411-420 (2008).
12. Padron Velazquez JL: Stem cell fusion as an ultimate line of defense against xenobiotics. Med. Hypotheses 67(2), 383-387 (2006).
13. Coldman A, Phillips N, Warren L, Kan L: Breast cancer mortality after screening mammography in British Columbia women. Int. J. Cancer 120(5), 1076-1080 (2007).
14. Doi K, Giger ML, Nishikawa RM, Schmidt RA: Computer-aided diagnosis of breast cancer on mammograms. Breast Cancer 4(4), 228-233 (1997).
15. Ilic D, O'Connor D, Green S, Wilt T: Screening for prostate cancer. Cochrane Database Syst. Rev. 3, CD004720 (2006).
16. Twombly R: Preventive Services Task Force recommends against PSA screening after age 75. J. Natl Cancer Inst. 100(22), 1571-1573 (2008).
17. Lipp HP, Hartmann JT: [Platinum compounds: metabolism, toxicity and supportive strategies]. Praxis (Bern. 1994) 94(6), 187-198 (2005).
18. Gouyette A, Deniel A, Pico JL et al.: Clinical pharmacology of high-dose etoposide associated with cisplatin. Pharmacokinetic and metabolic studies. Eur. J. Cancer Clin. Oncol. 23(11), 1627-1632 (1987).
19. Pera MF Jr, Sessford D, Roberts JJ: Toxicity of cisplatin and hydroxymalonatodiammine platinum (II) towards mouse bone marrow and B16 melanoma in relation to DNA binding in vivo. Biochem. Pharmacol. 31(13), 2273-2278 (1982).
20. Zinner RG, Herbst RS: Pemetrexed in the treatment of advanced non-small-cell lung cancer: a review of the clinical data. Clin. Lung Cancer 5(Suppl. 2), S67-S74 (2004).
21. Cohen MH, Williams GA, Sridhara R et al.: United States Food and Drug Administration Drug Approval summary: gefitinib (ZD1839; Iressa) tablets. Clin. Cancer Res. 10(4), 1212-1218 (2004).
22. Huddart RA, Birtle AJ: Recent advances in the treatment of testicular cancer. Expert Rev. Anticancer Ther. 5(1), 123-138 (2005).
23. Raghavan D: Testicular cancer: maintaining the high cure rate. Oncology 17(2), 218-228; discussion 228-229, 234-235, passim (2003).
24. Arora A, Scholar EM: Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315(3), 971-979 (2005).
25. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD: Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat. Rev. Cancer 7(5), 345-356 (2007).
26. Hahn EA, Glendenning GA: Quality of life on imatinib. Semin. Hematol. 40(2 Suppl. 2), 31-36 (2003).
27. Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I: Tyrosine kinase blockers: new hope for successful cancer therapy. Anticancer Agents Med. Chem. 9(1), 66-76 (2009).
28. Chang BS, Yang T, Cibas ES, Fletcher JA: An in vitro cytologic assay for evaluation of the KIT signaling pathway in gastrointestinal stromal tumors. Mod. Pathol. 20(5), 579-583 (2007).
29. Mauro MJ, Druker BJ: STI571: targeting BCR-ABL as therapy for CML. Oncologist 6(3), 233-238 (2001).
30. Druker B: Signal transduction inhibition: results from Phase I clinical trials in chronic myeloid leukemia. Semin. Hematol. 38(3 Suppl. 8), 9-14 (2001).
31. Booth RA: Minimally invasive biomarkers for detection and staging of colorectal cancer. Cancer Lett. 249(1), 87-96 (2007).
32. Watanabe N: [Oncogene and tumor suppressor gene]. Rinsho Byori Suppl. 123, 131-136 (2002).
33. Nagai H, Harada H, Emi M: [Oncogene and tumor suppressor gene]. Nippon Rinsho 58(Suppl.), 25-29 (2000).
34. Zhang WW: Antisense oncogene and tumor suppressor gene therapy of cancer. J. Mol. Med. 74(4), 191-204 (1996).
35. Fearon ER, Dang CV: Cancer genetics: tumor suppressor meets oncogene. Curr. Biol. 9(2), R62-R65 (1999).
36. Sung J, Turner J, McCarthy S et al.: Oncogene regulation of tumor suppressor genes in tumorigenesis. Carcinogenesis 26(2), 487-494 (2005).
37. Menke AL, van der Eb AJ, Jochemsen AG: The Wilms' tumor 1 gene: oncogene or tumor suppressor gene? Int. Rev. Cytol. 181, 151-212 (1998).
38. Stiewe T, Putzer BM: Role of p73 in malignancy: tumor suppressor or oncogene? Cell Death Differ. 9(3), 237-245 (2002).
39. Frank JL, Bur ME, Garb JL et al.: p53 tumor suppressor oncogene expression in squamous cell carcinoma of the hypopharynx. Cancer 73(1), 181-186 (1994).
40. Kossatz U, Malek NP: p27: tumor suppressor and oncogene ...? Cell Res. 17(10), 832-833 (2007).
41. Damm K: ErbA: tumor suppressor turned oncogene? FASEB J. 7(10), 904-909 (1993).
42. Johnson DG: The paradox of E2F1: oncogene and tumor suppressor gene: Mol. Carcinog. 27(3), 151-157 (2000).
43. Lu Q, Zhang J, Chen Y-H: Prostate cancer cell growth and death: complex roles of pro-and anti-oncogenic protein signaling. In: Handbook of Prostate Cancer Cell Research: Growth, Signalling and Survival. Meridith AT (Ed.). Nova Science Pub Inc., NY, USA, 431-447 (2009).
44. Borges HL, Bird J, Wasson K et al.: Tumor promotion by caspase-resistant retinoblastoma protein. Proc. Natl Acad. Sci. USA 102(43), 15587-15592 (2005).
45. Wang D, Russell JL, Johnson DG: E2F4 and E2F1 have similar proliferative properties but different apoptotic and oncogenic properties in vivo. Mol. Cell. Biol. 20(10), 3417-3424 (2000).
46. Davis JN, Wojno KJ, Daignault S et al.: Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res. 66(24), 11897-11906 (2006).
47. Kaseb AO, Chinnakannu K, Chen D et al.: Androgen receptor and E2F-1 targeted thymoquinone therapy for hormone-refractory prostate cancer. Cancer Res. 67(16), 7782-7788 (2007).
48. Rogoff HA, Kowalik TF: Life, death and E2F: linking proliferation control and DNA damage signaling via E2F1. Cell Cycle 3(7), 845-846 (2004).
49. Nakajima Y: [Interaction of E2F/Rb family members with factor binding to co-repressor element on B-myb and E2F1 promoters]. Kokubyo Gakkai Zasshi 65(2), 172-188 (1998).
50. Rogoff HA, Pickering MT, Debatis ME, Jones S, Kowalik TF: E2F1 induces phosphorylation of p53 that is coincident with p53 accumulation and apoptosis. Mol. Cell. Biol. 22(15), 5308-5318 (2002).
51. de Caestecker MP, Piek E, Roberts AB: Role of transforming growth factor-b signaling in cancer. J. Natl Cancer Inst. 92(17), 1388-1402 (2000).
52. Schnaper HW, Hayashida T, Hubchak SC, Poncelet AC: TGF-b signal transduction and mesangial cell fibrogenesis. Am. J. Physiol. Renal Physiol. 284(2), F243-F2452 (2003).
53. Glick AB: TGF-b1, back to the future: revisiting its role as a transforming growth factor. Cancer Biol. Ther. 3(3), 276-283 (2004).
54. Oft M, Akhurst RJ, Balmain A: Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat. Cell Biol. 4(7), 487-494 (2002).
55. Shi Y, Massague J: Mechanisms of TGF-b signaling from cell membrane to the nucleus. Cell 113(6), 685-700 (2003).
56. Amendt C, Schirmacher P, Weber H, Blessing M: Expression of a dominant negative type II TGF-b receptor in mouse skin results in an increase in carcinoma incidence and an acceleration of carcinoma development. Oncogene 17(1), 25-34 (1998).
57. Blessing M, Nanney LB, King LE, Hogan BL: Chemical skin carcinogenesis is prevented in mice by the induced expression of a TGF-b related transgene. Teratog. Carcinog. Mutagen. 15(1), 11-21 (1995).
58. Glick AB, Lee MM, Darwiche N et al.: Targeted deletion of the TGF-b1 gene causes rapid progression to squamous cell carcinoma. Genes Dev. 8(20), 2429-2440 (1994).
59. Wang XJ, Greenhalgh DA, Bickenbach JR et al.: Expression of a dominant-negative type II transforming growth factor b (TGF-b) receptor in the epidermis of transgenic mice blocks TGF-b-mediated growth inhibition. Proc. Natl Acad. Sci. USA 94(6), 2386-2391 (1997).
60. Cui W, Fowlis DJ, Bryson S et al.: TGF-b1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 86(4), 531-542 (1996).
61. Weeks BH, He W, Olson KL, Wang XJ: Inducible expression of transforming growth factor b1 in papillomas causes rapid metastasis. Cancer Res. 61(20), 7435-7443 (2001).
62. He W, Cao T, Smith DA, Myers TE, Wang XJ: Smads mediate signaling of the TGF-b superfamily in normal keratinocytes but are lost during skin chemical carcinogenesis. Oncogene 20(4), 471-483 (2001).
63. Vijayachandra K, Lee J, Glick AB: Smad3 regulates senescence and malignant conversion in a mouse multistage skin carcinogenesis model. Cancer Res. 63(13), 3447-3452 (2003).
64. Li AG, Lu SL, Zhang MX, Deng C, Wang XJ: Smad3 knockout mice exhibit a resistance to skin chemical carcinogenesis. Cancer Res. 64(21), 7836-7845 (2004).
65. Peifer M, Berg S, Reynolds AB: A repeating amino acid motif shared by proteins with diverse cellular roles. Cell 76(5), 789-791 (1994).
66. Lu Q, Paredes M, Medina M et al.: d-catenin, an adhesive junction-associated protein which promotes cell scattering. J. Cell. Biol. 144(3), 519-532 (1999).
67. Paffenholz R, Franke WW: Identification and localization of a neurally expressed member of the plakoglobin/armadillo multigene family. Differentiation 61(5), 293-304 (1997).
68. Zhou J, Liyanage U, Medina M et al.: Presenilin 1 interaction in the brain with a novel member of the armadillo family. Neuroreport 8(6), 1489-1494 (1997). (Pubitemid 27242561)
69. Thoreson MA, Reynolds AB: Altered expression of the catenin p120 in human cancer: implications for tumor progression. Differentiation 70(9-10), 583-589 (2002).
70. Anastasiadis PZ, Moon SY, Thoreson MA et al.: Inhibition of RhoA by p120 catenin. Nat. Cell Biol. 2(9), 637-644 (2000).
71. Noren NK, Liu BP, Burridge K, Kreft B: p120 catenin regulates the actin cytoskeleton via Rho family GTPases. J. Cell. Biol. 150(3), 567-580 (2000).
72. Ireton RC, Davis MA, van Hengel J et al.: A novel role for p120 catenin in E-cadherin function. J. Cell. Biol. 159(3), 465-476 (2002).
73. Lu Q, Dobbs LJ, Gregory CW et al.: Increased expression of d-catenin/neural plakophilin-related armadillo protein is associated with the down-regulation and redistribution of E-cadherin and p120ctn in human prostate cancer. Hum. Pathol. 36(10), 1037-1048 (2005).
74. Lu Q, Mukhopadhyay NK, Griffin JD et al.: Brain armadillo protein d-catenin interacts with Abl tyrosine kinase and modulates cellular morphogenesis in response to growth factors. J. Neurosci. Res. 67(5), 618-624 (2002).
75. Kim K, Oh M, Ki H et al.: Identification of E2F1 as a positive transcriptional regulator for d-catenin. Biochem. Biophys. Res. Commun. 369(2), 414-420 (2008).
76. Zeng Y, Abdallah A, Lu JP et al.: d-catenin promotes prostate cancer cell growth and progression by altering cell cycle and survival gene profiles. Mol. Cancer 8, 19 (2009).
77. Debusk LM, Boelte K, Min Y, Lin PC: Heterozygous deficiency of d-catenin impairs pathological angiogenesis. J. Exp. Med. 207(1), 77-84 (2010).
78. Kim K, Sirota A, Chen Yh YH et al.: Dendrite-like process formation and cytoskeletal remodeling regulated by d-catenin expression. Exp. Cell Res. 275(2), 171-184 (2002).
79. Westbrook TF, Martin ES, Schlabach MR et al.: A genetic screen for candidate tumor suppressors identifies REST. Cell 121(6), 837-848 (2005).
80. Bader AG, Kang S, Zhao L, Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer 5(12), 921-929 (2005).
81. Engelman JA, Luo J, Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat. Rev. Genet. 7(8), 606-619 (2006).
82. Brugge J, Hung MC, Mills GB: A new mutational AKTivation in the PI3K pathway. Cancer Cell 12(2), 104-107 (2007).
83. Gymnopoulos M, Elsliger MA, Vogt PK: Rare cancer-specific mutations in PIK3CA show gain of function. Proc. Natl Acad. Sci. USA 104(13), 5569-5574 (2007).
84. Ikenoue T, Kanai F, Hikiba Y et al.: Functional analysis of PIK3CA gene mutations in human colorectal cancer. Cancer Res. 65(11), 4562-4567 (2005).
85. Kang S, Bader AG, Vogt PK: Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl Acad. Sci. USA 102(3), 802-807 (2005).
86. Bader AG, Kang S, Vogt PK: Cancer-specific mutations in PIK3CA are oncogenic in vivo. Proc. Natl Acad. Sci. USA 103(5), 1475-1479 (2006).
87. Isakoff SJ, Engelman JA, Irie HY et al.: Breast cancer-associated PIK3CA mutations are oncogenic in mammary epithelial cells. Cancer Res. 65(23), 10992-11000 (2005).
88. Zhao JJ, Liu Z, Wang L et al.: The oncogenic properties of mutant p110aand p110b phosphatidylinositol 3-kinases in human mammary epithelial cells. Proc. Natl Acad. Sci. USA 102(51), 18443-18448 (2005).
89. Samuels Y, Diaz LA Jr, Schmidt-Kittler O et al.: Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7(6), 561-573 (2005).
90. Miyauchi H, Minamino T, Tateno K et al.: Akt negatively regulates the in vitro lifespan of human endothelial cells via a p53/p21-dependent pathway. EMBO J. 23(1), 212-220 (2004).
91. Oyama K, Okawa T, Nakagawa H et al.: AKT induces senescence in primary esophageal epithelial cells but is permissive for differentiation as revealed in organotypic culture. Oncogene 26(16), 2353-2364 (2007).
92. Blanco-Aparicio C, Pérez-Gallego L, Pequeño B, Leal JF, Renner O, Carnero A. Mice expressing myrAKT1 in the mammary gland develop carcinogen-induced ER-positive mammary tumors that mimic human breast cancer. Carcinogenesis 28(3), 584-594 (2007).
93. Hutchinson JN, Jin J, Cardiff RD, Woodgett JR, Muller WJ: Activation of Akt-1 (PKB-a) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. Cancer Res. 64(9), 3171-3178 (2004).
94. Renner O, Blanco-Aparicio C, Grassow M et al.: Activation of phosphatidylinositol 3-kinase by membrane localization of p110apredisposes mammary glands to neoplastic transformation. Cancer Res. 68(23), 9643-9653 (2008).
95. Buttitta F, Felicioni L, Barassi F et al.: PIK3CA mutation and histological type in breast carcinoma: high frequency of mutations in lobular carcinoma. J. Pathol. 208(3), 350-355 (2006).
96. Campbell IG, Russell SE, Choong DY et al.: Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64(21), 7678-7681 (2004).
97. Li SY, Rong M, Grieu F, Iacopetta B: PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Res. Treat. 96(1), 91-95 (2006).
98. Maruyama N, Miyoshi Y, Taguchi T et al.: Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women. Clin. Cancer Res. 13(2 Pt 1), 408-414 (2007).
99. Saal LH, Holm K, Maurer M et al.: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65(7), 2554-2559 (2005).
100. Samuels Y, Wang Z, Bardelli A et al.: High frequency of mutations of the PIK3CA gene in human cancers. Science 304(5670), 554 (2004). (Pubitemid 38541907)
101. Kalinsky K, Jacks LM, Heguy A et al.: PIK3CA mutation associates with improved outcome in breast cancer. Clin. Cancer Res. 15(16), 5049-5059 (2009).
102. Di Cosimo S, Baselga J: Phosphoinositide 3-kinase mutations in breast cancer: a "good" activating mutation? Clin. Cancer Res. 15(16), 5017-5019 (2009).
103. Pritchard JR, Cosgrove BD, Hemann MT, Griffith LG, Wands JR, Lauffenburger DA: Three-kinase inhibitor combination recreates multipathway effects of a geldanamycin analogue on hepatocellular carcinoma cell death. Mol. Cancer Ther. 8(8), 2183-2192 (2009).
104. Basso AD, Solit DB, Munster PN, Rosen N: Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2. Oncogene 21(8), 1159-1166 (2002).
105. Neshat MS, Mellinghoff IK, Tran C et al.: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 98(18), 10314-10319 (2001).
106. Gulhati P, Cai Q, Li J et al.: Targeted inhibition of mammalian target of rapamycin signaling inhibits tumorigenesis of colorectal cancer. Clin. Cancer Res. 15(23), 7207-7216 (2009).
107. Johnson R, Spiegelman B, Hanahan D, Wisdom R: Cellular transformation and malignancy induced by ras require c-jun. Mol. Cell. Biol. 16(8), 4504-4511 (1996).
108. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 100(1), 57-70 (2000).
109. Downward J: Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 3(1), 11-22 (2003).
110. Torii S, Yamamoto T, Tsuchiya Y, Nishida E: ERK MAP kinase in G cell cycle progression and cancer. Cancer Sci. 97(8), 697-702 (2006).
111. Schaeffer HJ, Weber MJ: Mitogen-activated protein kinases: specific messages from ubiquitous messengers. Mol. Cell. Biol. 19(4), 2435-2444 (1999).
112. Chen N, Nomura M, She QB et al.: Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice. Cancer Res. 61(10), 3908-3912 (2001).
113. Kyriakis JM, Avruch J: Mammalian mitogen-activated protein kinase signal transduction pathways activated by stress and inflammation. Physiol. Rev. 81(2), 807-869 (2001).
114. Krens SF, He S, Spaink HP, Snaar-Jagalska BE: Characterization and expression patterns of the MAPK family in zebrafish. Gene Expr. Patterns 6(8), 1019-1026 (2006).
115. Friday BB, Adjei AA: Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clin. Cancer Res. 14(2), 342-346 (2008).
116. Leicht DT, Balan V, Kaplun A et al.: Raf kinases: function, regulation and role in human cancer. Biochim. Biophys. Acta 1773(8), 1196-1212 (2007).
117. Young A, Lyons J, Miller AL et al.: Ras signaling and therapies. Adv. Cancer Res. 102, 1-17 (2009).
118. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F et al.: Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res. 67(6), 2643-2648 (2007).
119. Dhillon AS, Hagan S, Rath O, Kolch W: MAP kinase signalling pathways in cancer. Oncogene 26(22), 3279-3290 (2007).
120. Yu C, Krystal G, Varticovksi L et al.: Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with STI571 to induce apoptosis in Bcr/ Abl-expressing human leukemia cells. Cancer Res. 62(1), 188-199 (2002). (Pubitemid 34074004)
121. Allen LF, Sebolt-Leopold J, Meyer MB: CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin. Oncol. 30(5 Suppl. 16), 105-116 (2003). (Pubitemid 37433401)
122. Milella M, Kornblau SM, Estrov Z et al.: Therapeutic targeting of the MEK/MAPK signal transduction module in acute myeloid leukemia. J. Clin. Invest. 108(6), 851-859 (2001). (Pubitemid 32880294)
123. Wong KK: Recent developments in anti-cancer agents targeting the Ras/Raf/ MEK/ERK pathway. Recent Pat. Anticancer Drug Discov. 4(1), 28-35 (2009).
124. Greene LA, Tischler AS: Establishment of a noradrenergic clonal line of rat adrenal pheochromocytoma cells which respond to nerve growth factor. Proc. Natl Acad. Sci. USA 73(7), 2424-2428 (1976).
125. Huff K, End D, Guroff G: Nerve growth factor-induced alteration in the response of PC12 pheochromocytoma cells to epidermal growth factor. J. Cell. Biol. 88(1), 189-198 (1981). (Pubitemid 11174050)
126. Marshall CJ: Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80(2), 179-185 (1995).
127. Bodo J, Duraj J, Jakubikova J, Sedlak J: Isothiocyanate E-4IB induces MAPK activation, delayed cell cycle transition and apoptosis. Cell Prolif. 40(3), 316-326 (2007). (Pubitemid 46802186)
128. McCubrey JA, Steelman LS, Abrams SL et al.: Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 46, 249-279 (2006).
129. Hoyle PE, Moye PW, Steelman LS et al.: Differential abilities of the Raf family of protein kinases to abrogate cytokine dependency and prevent apoptosis in murine hematopoietic cells by a MEK1-dependent mechanism. Leukemia 14(4), 642-656 (2000).
130. Chang F, McCubrey JA: p21(Cip1) induced by Raf is associated with increased Cdk4 activity in hematopoietic cells. Oncogene 20(32), 4354-4364 (2001). (Pubitemid 32726877)
131. Chang F, Steelman LS, McCubrey JA: Raf-induced cell cycle progression in human TF-1 hematopoietic cells. Cell Cycle 1(3), 220-226 (2002).
132. Sanders MR, Lu H, Walker F, Sorba S, Dainiak N: The Raf-1 protein mediates insulin-like growth factor-induced proliferation of erythroid progenitor cells. Stem Cells 16(3), 200-207 (1998). (Pubitemid 28235164)
133. Cioffi CL, Garay M, Johnston JF et al.: Selective inhibition of A-Raf and C-Raf mRNA expression by antisense oligodeoxynucleotides in rat vascular smooth muscle cells: role of A-Raf and C-Raf in serum-induced proliferation. Mol. Pharmacol. 51(3), 383-389 (1997). (Pubitemid 27118473)
134. Yen A, Williams M, Platko JD, Der C, Hisaka M: Expression of activated RAF accelerates cell differentiation and RB protein down-regulation but not hypophosphorylation. Eur. J. Cell Biol. 65(1), 103-113 (1994). (Pubitemid 24328182)
135. Ravi RK, Weber E, McMahon M et al.: Activated Raf-1 causes growth arrest in human small cell lung cancer cells. J. Clin. Invest. 101(1), 153-159 (1998). (Pubitemid 28058914)
136. Lloyd AC, Obermuller F, Staddon S et al.: Cooperating oncogenes converge to regulate cyclin/cdk complexes. Genes Dev. 11(5), 663-677 (1997). (Pubitemid 27133385)
137. Woods D, Parry D, Cherwinski H et al.: Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol. Cell. Biol. 17(9), 5598-5611 (1997). (Pubitemid 27357656)
138. Shelton JG, Chang F, Lee JT et al.: B-raf and insulin synergistically prevent apoptosis and induce cell cycle progression in hematopoietic cells. Cell Cycle 3(2), 189-196 (2004). (Pubitemid 40268696)
139. Shelton JG, Steelman LS, White ER, McCubrey JA: Synergy between PI3K/Akt and Raf/MEK/ERK pathways in IGF-1R mediated cell cycle progression and prevention of apoptosis in hematopoietic cells. Cell Cycle 3(3), 372-379 (2004).
140. Lee JT Jr, Steelman LS, McCubrey JA: Modulation of Raf/MEK/ERK kinase activity does not affect the chemoresistance profile of advanced prostate cancer cells. Int. J. Oncol. 26(6), 1637-1644 (2005).
141. Lee JT Jr, McCubrey JA: The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. Leukemia 16(4), 486-507 (2002).
142. Lane DP: Cancer-p53, guardian of the genome. Nature 358(6381), 15-16 (1992).
143. Smith ML, Lancia JK, Mercer TI, Ip C: Selenium compounds regulate p53 by common and distinctive mechanisms. Anticancer Res. 24(3A), 1401-1408 (2004). (Pubitemid 38954655)
144. Beaudry GA, Bertelsen AH, Sherman MI: Therapeutic targeting of the p53 tumor suppressor gene. Curr. Opin. Biotechnol. 7(6), 592-600 (1996). (Pubitemid 26400061)
145. Milner J: Structures and functions of the tumor suppressor p53. Pathol. Biol. (Paris) 45(10), 797-803 (1997). (Pubitemid 28109052)
146. Strano S, Dell'Orso S, Di Agostino S et al. Mutant p53: an oncogenic transcription factor. Oncogene 26(15), 2212-2219 (2007). (Pubitemid 46536646)
147. Wiman KG: Restoration of wild-type p53 function in human tumors: strategies for efficient cancer therapy. Adv. Cancer Res. 97, 321-338 (2007). (Pubitemid 46528994)
148. Roth JA, Swisher SG, Meyn RE: p53 tumor suppressor gene therapy for cancer. Oncology 13(10 Suppl. 5), 148-154 (1999).
149. Foster BA, Coffey HA, Morin MJ, Rastinejad F: Pharmacological rescue of mutant p53 conformation and function. Science 286(5449), 2507-2510 (1999). (Pubitemid 30026339)
150. Mrass P, Rendl M, Mildner M et al.: Retinoic acid increases the expression of p53 and proapoptotic caspases and sensitizes keratinocytes to apoptosis: a possible explanation for tumor preventive action of retinoids. Cancer Res. 64(18), 6542-6548 (2004). (Pubitemid 39297912)
151. Hsu SL, Hsu JW, Liu MC, Chen LY, Chang CD: Retinoic acid-mediated G1 arrest is associated with induction of p27(Kip1) and inhibition of cyclin-dependent kinase 3 in human lung squamous carcinoma CH27 cells. Exp. Cell Res. 258(2), 322-331 (2000).
152. Falasca L, Favale A, Gualandi G, Maietta G, Conti Devirgiliis L: Retinoic acid treatment induces apoptosis or expression of a more differentiated phenotype on different fractions of cultured fetal rat hepatocytes. Hepatology 28(3), 727-737 (1998).
153. Gallahan D, Kozak C, Callahan R: A new common integration region (int-3) for mouse mammary tumor virus on mouse chromosome 17. J. Virol. 61(1), 218-220 (1987).
154. Efstratiadis A, Szabolcs M, Klinakis A: Notch, Myc and breast cancer. Cell Cycle 6(4), 418-429 (2007).
155. Callahan R, Egan SE: Notch signaling in mammary development and oncogenesis. J. Mammary Gland Biol. Neoplasia 9(2), 145-163 (2004).
156. Weeraratna AT, Jiang Y, Hostetter G et al.: Wnt5a signaling directly affects cell motility and invasion of metastatic melanoma. Cancer Cell 1(3), 279-288 (2002).
157. Callahan R, Raafat A: Notch signaling in mammary gland tumorigenesis. J. Mammary Gland Biol. Neoplasia 6(1), 23-36 (2001).
158. Hu C, Dievart A, Lupien M et al.: Overexpression of activated murine Notch1 and Notch3 in transgenic mice blocks mammary gland development and induces mammary tumors. Am. J. Pathol. 168(3), 973-990 (2006).
159. Miyamoto Y, Maitra A, Ghosh B et al.: Notch mediates TGF-a-induced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 3(6), 565-576 (2003).
160. Koch U, Radtke F: Notch and cancer: a double-edged sword. Cell Mol. Life Sci. 64(21), 2746-2762 (2007).
161. Nicolas M, Wolfer A, Raj K et al.: Notch1 functions as a tumor suppressor in mouse skin. Nature Genet. 33(3), 416-421 (2003).
162. Nguyen BC, Lefort K, Mandinova A et al.: Cross-regulation between Notch and p63 in keratinocyte commitment to differentiation. Genes Dev. 20(8), 1028-1042 (2006).
163. Lowell S, Jones P, Le Roux I, Dunne J, Watt FM: Stimulation of human epidermal differentiation by d-Notch signalling at the boundaries of stem-cell clusters. Curr. Biol. 10(9), 491-500 (2000).
164. Rangarajan A, Talora C, Okuyama R et al.: Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 20(13), 3427-3436 (2001).
165. Vauclair S, Nicolas M, Barrandon Y, Radtke F: Notch1 is essential for postnatal hair follicle development and homeostasis. Dev. Biol. 284(1), 184-193 (2005).
166. Weinmaster G: The ins and outs of Notch signalling. Mol. Cell. Neurosci. 9(2), 91-102 (1997).
167. Engin F, Bertin T, Ma O et al.: Notch signaling contributes to the pathogenesis of human osteosarcomas. Hum. Mol. Genet. 18(8), 1464-1470 (2009).
168. Villaronga MA, Bevan CL, Belandia B: Notch signaling: a potential therapeutic target in prostate cancer. Curr. Cancer Drug Targets 8(7), 566-580 (2008).
169. Katoh M: Notch signaling in gastrointestinal tract (review). Int. J. Oncol. 30(1), 247-251 (2007).
170. Leong KG, Gao WQ: The Notch pathway in prostate development and cancer. Differentiation 76(6), 699-716 (2008).
171. Zhang Y, Lian JB, Stein JL, van Wijnen AJ, Stein GS: The Notch-responsive transcription factor Hes-1 attenuates osteocalcin promoter activity in osteoblastic cells. J. Cell. Biochem. 108(3), 651-659 (2009).
172. Zayzafoon M, Abdulkadir SA, McDonald JM: Notch signaling and ERK activation are important for the osteomimetic properties of prostate cancer bone metastatic cell lines. J. Biol. Chem. 279(5), 3662-3670 (2004).
173. Scorey N, Fraser SP, Patel P et al.: Notch signalling and voltage-gated Na+ channel activity in human prostate cancer cells: independent modulation of in vitro motility. Prostate Cancer Prostatic Dis. 9(4), 399-406 (2006).
174. Strom A, Arai N, Leers J, Gustafsson JA: The hairy and enhancer of split homologue-1 (HES-1) mediates the proliferative effect of 17b-estradiol on breast cancer cell lines. Oncogene 19(51), 5951-5953 (2000).
175. Johansson T, Lejonklou MH, Ekeblad S, Stalberg P, Skogseid B: Lack of nuclear expression of hairy and enhancer of split-1 (HES1) in pancreatic endocrine tumors. Horm. Metab. Res. 40(5), 354-359 (2008).
176. Zhang P, Yang Y PA, Zweidler-McKay, Hughes DP: Critical role of Notch signaling in osteosarcoma invasion and metastasis. Clin. Cancer Res. 14(10), 2962-2969 (2008).
177. Nickoloff BJ, Osborne BA, Miele L: Notch signaling as a therapeutic target in cancer: a new approach to the development of cell fate modifying agents. Oncogene 22(42), 6598-6608 (2003).
178. Wong GT, Manfra D, Poulet FM et al.: Chronic treatment with the g-secretase inhibitor LY-411,575 inhibits b-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J. Biol. Chem. 279(13), 12876-12882 (2004).
179. Spiegel D, Sephton SE: Psychoneuroimmune and endocrine pathways in cancer: effects of stress and support. Semin. Clin. Neuropsychiatry 6(4), 252-265 (2001).
180. McGregor BA, Antoni MH: Psychological intervention and health outcomes among women treated for breast cancer: a review of stress pathways and biological mediators. Brain Behav. Immun. 23(2), 159-166 (2009).
181. Andersen BL, Farrar WB, Golden-Kreutz D et al.: Stress and immune responses after surgical treatment for regional breast cancer. J. Natl Cancer Inst. 90(1), 30-36 (1998).
182. Coker AL, Sanderson M, Ellison GL, Fadden MK: Stress, coping, social support, and prostate cancer risk among older African American and Caucasian men. Ethn. Dis. 16(4), 978-987 (2006).
183. Giese-Davis J, Wilhelm FH, Conrad A et al.: Depression and stress reactivity in metastatic breast cancer. Psychosom. Med. 68(5), 675-683 (2006).
184. Vanacore N, Spila-Alegiani S, Raschetti R, Meco G: Mortality cancer risk in parkinsonian patients: a population-based study. Neurology 52(2), 395-398 (1999).
185. D'Amelio M, Ragonese P, Morgante L et al.: Tumor diagnosis preceding Parkinson's disease: a case-control study. Mov. Disord. 19(7), 807-811 (2004).
186. Olsen JH, Friis S, Frederiksen K et al.: Atypical cancer pattern in patients with Parkinson's disease. Br. J. Cancer 92(1), 201-205 (2005).
187. Roe CM, Fitzpatrick AL, Xiong C et al.: Cancer linked to Alzheimer disease but not vascular dementia. Neurology 74, 106-112 (2010).
188. Buchler P, Reber HA, Roth MM et al.: Target therapy using a small molecule inhibitor against angiogenic receptors in pancreatic cancer. Neoplasia 9(2), 119-127 (2007).
189. Pasetto LM, Bortolami A, Falci C, Sinigaglia G, Monfardini S: Recent progress in target therapy in colorectal cancer. Anticancer Res. 26(5B), 3973-3981 (2006).
190. Midgley RS, Kerr DJ: Ras as a target in cancer therapy. Crit. Rev. Oncol.
191. Kelley JR, Brown JM, Frasier MM et al.: The cancer-associated Sm-like oncogene: a novel target for the gene therapy of pancreatic cancer. Surgery 128(2), 353-360 (2000).
192. Jimeno A, Daw NC, Amador ML et al.: Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. Pediatr. Blood Cancer 49(3), 352-357 (2007).
193. Epstein RJ: Maintenance therapy to suppress micrometastasis: the new challenge for adjuvant cancer treatment. Clin. Cancer Res. 11(15), 5337-5341 (2005).
194. Chari RV: Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc. Chem. Res. 41(1), 98-107 (2008).
195. Gelber RD, Bonetti M, Castiglione-Gertsch M, Coates AS, Goldhirsch A; International Breast Cancer Study Group (IBCSG): Tailoring adjuvant treatments for the individual breast cancer patient. Breast 12(6), 558-568 (2003).
196. Hamberg P, Verweij J, Seynaeve C: Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy. Eur. J. Cancer 43(10), 1514-1528 (2007).
197. Briest S, Stearns V: Chemotherapeutic strategies for advanced breast cancer. Oncology 21(11), 1325-1335; discussion 1338, 1340 (2007).
198. Rong Y, Jin D, Wu W et al.: Induction of protective and therapeutic anti-pancreatic cancer immunity using a reconstructed MUC1 DNA vaccine. BMC Cancer 9, 191 (2009).
199. Taghavi P, Verhoeven E, Jacobs JJ et al.: In vitro genetic screen identifies a cooperative role for LPA signaling and c-Myc in cell transformation. Oncogene 27, 6806-6816 (2008).
200. Iaquinta PJ, Lees JA: Life and death decisions by the E2F transcription factors. Curr. Opin. Cell Biol. 19(6), 649-657 (2007).
201. Pierce AM, Schneider-Broussard R, Gimenez-Conti IB et al.: E2F1 has both oncogenic and tumor-suppressive properties in a transgenic model. Mol. Cell. Biol. 19(9), 6408-6414 (1999).
202. Fisher GH, Wellen SL, Klimstra D et al.: Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15(24), 3249-3262 (2001).
203. Macias-Perez I, Borza C, Chen X et al.: Loss of integrin a1b1 ameliorates Kras-induced lung cancer. Cancer Res. 68(15), 6127-6135 (2008).
204. Zhang Z, Wang Y, Vikis HG et al.: Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat. Genet. 29(1), 25-33 (2001).
205. Cho NY, Choi M, Kim BH et al.: BRAF and KRAS mutations in prostatic adenocarcinoma. Int. J. Cancer 119(8), 1858-1862 (2006).
206. Allen PB, Wiedemann LM: An activating mutation in the ATP binding site of the ABL kinase domain. J. Biol. Chem. 271(32), 19585-19591 (1996).
207. Jackson P, Baltimore D: N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J. 8(2), 449-456 (1989).
208. Carter TA, Wodicka LM, Shah NP et al.: Inhibition of drug-resistant mutants of ABL, KIT, EGF receptor kinases. Proc. Natl Acad. Sci. USA 102(31), 11011-11016 (2005).
209. Cordon-Cardo C, Reuter VE: Alterations of tumor suppressor genes in bladder cancer. Semin. Diagn. Pathol. 14(2), 123-132 (1997). (Pubitemid 27233150)
210. Sakata K: Alterations of tumor suppressor genes and the H-ras oncogene in oral squamous cell carcinoma. J. Oral Pathol. Med. 25(6), 302-307 (1996).
211. Zhou H, Kuang J, Zhong L et al.: Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation. Nat. Genet. 20(2), 189-193 (1998).
212. Lu LY, Wood JL, Ye L et al.: Aurora a is essential for early embryonic development and tumor suppression. J. Biol. Chem. 283(46), 31785-31790 (2008).
213. Weinberg BD, Ai H, Blanco E, Anderson JM, Gao J: Antitumor efficacy and local distribution of doxorubicin via intratumoral delivery from polymer millirods. J. Biomed. Mater. Res. A 81(1), 161-170 (2007).
214. Polakis P: Wnt signaling and cancer. Genes Dev. 14(15), 1837-1851 (2000).
215. Voeller HJ, Truica CI, Gelmann EP: b-catenin mutations in human prostate cancer. Cancer Res. 58(12), 2520-2523 (1998).
216. Chesire DR, Ewing CM, Sauvageot J, Bova GS, Isaacs WB: Detection and analysis of b-catenin mutations in prostate cancer. Prostate 45(4), 323-334 (2000).
217. Kim K, Pang KM, Evans M, Hay ED: Overexpression of b-catenin induces apoptosis independent of its transactivation function with LEF-1 or the involvement of major G1 cell cycle regulators. Mol. Biol. Cell 11(10), 3509-3523 (2000).
218. Terry S, Yang X, Chen MW, Vacherot F, Buttyan R: Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J. Cell. Biochem. 99(2), 402-410 (2006). (Pubitemid 44435558)
219. Yang X, Chen MW, Terry S et al.: Complex regulation of human androgen receptor expression by Wnt signaling in prostate cancer cells. Oncogene 25(24), 3436-3444 (2006).
220. Yu X, Wang Y, Jiang M et al.: Activation of b-catenin in mouse prostate causes HGPIN and continuous prostate growth after castration. Prostate 69(3), 249-262 (2009).
221. Kinzler KW, Vogelstein B: Lessons from hereditary colorectal cancer. Cell 87(2), 159-170 (1996).
222. Hanson CA, Miller JR: Non-traditional roles for the adenomatous polyposis coli (APC) tumor suppressor protein. Gene 361, 1-12 (2005).
223. Dobosy JR, Roberts JL, Fu VX, Jarrard DF: The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J. Urol. 177(3), 822-831 (2007).
224. Kawasaki Y, Sato R, Akiyama T: Mutated APC and Asef are involved in the migration of colorectal tumour cells. Nat. Cell Biol. 5(3), 211-215 (2003).
225. Tighe A, Johnson VL, Taylor SS: Truncating APC mutations have dominant effects on proliferation, spindle checkpoint control, survival and chromosome stability. J. Cell. Sci. 117(Pt 26), 6339-6353 (2004).
226. Caldwell CM, Green RA, Kaplan KB: APC mutations lead to cytokinetic failures in vitro and tetraploid genotypes in Min mice. J. Cell. Biol. 178(7), 1109-1120 (2007).
227. Kallakury BV, Sheehan CE, Ross JS: Co-downregulation of cell adhesion proteins a-and b-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. Hum. Pathol. 32(8), 849-855 (2001).
228. Nagafuchi A, Takeichi M, Tsukita S: The 102 kd cadherin-associated protein: similarity to vinculin and posttranscriptional regulation of expression. Cell 65(5), 849-857 (1991).
229. Papkoff J: Regulation of complexed and free catenin pools by distinct mechanisms. Differential effects of Wnt-1 and v-Src. J. Biol. Chem. 272(7), 4536-4543 (1997).
230. Anastasiadis PZ, Reynolds AB: Regulation of Rho GTPases by p120-catenin. Curr. Opin. Cell Biol. 13(5), 604-610 (2001).
231. Noren NK, Liu BP, Burridge K, Kreft B: p120 catenin regulates the actin cytoskeleton via Rho family GTPases. J. Cell. Biol. 150(3), 567-580 (2000).
232. Reynolds AB, Jenkins NA, Gilbert DJ et al.: The gene encoding p120cas, a novel catenin, localizes on human chromosome 11q11 (CTNND) and mouse chromosome 2 (Catns). Genomics 31(1), 127-129 (1996).
233. Thoreson MA, Anastasiadis PZ, Daniel JM et al.: Selective uncoupling of p120ctn from E-cadherin disrupts strong adhesion. J. Cell. Biol. 148(1), 189-202 (2000).
234. Wang T, Chen YH, Hong H et el.: Increased nucleotide polymorphic changes in the 5́-untranslated region of d-catenin (CTNND2) gene in prostate cancer. Oncogene 28(4), 555-564 (2009).
235. Burger MJ, Tebay MA, Keith PA et al.: Expression analysis of d-catenin and prostate-specific membrane antigen: their potential as diagnostic markers for prostate cancer. Int. J. Cancer 100(2), 228-237 (2002).
236. Sylvestre Y, De Guire V, Querido E et al.: An E2F/miR-20a autoregulatory feedback loop. J. Biol. Chem. 282(4), 2135-2143 (2007).
237. Galardi S, Mercatelli N, Giorda E et al.: miR-221 and miR-222 expression affects the proliferation potential of human prostate carcinoma cell lines by targeting p27Kip1. J. Biol. Chem. 282(32), 23716-23724 (2007).
238. Shi XB, Tepper CG, White RW: MicroRNAs and prostate cancer. J. Cell. Mol. Med. 12(5A), 1456-1465 (2008).
239. Musiyenko A, Bitko V, Barik S: Ectopic expression of miR-126*, an intronic product of the vascular endothelial EGF-like 7 gene, regulates prostein translation and invasiveness of prostate cancer LNCaP cells. J. Mol. Med. 86(3), 313-322 (2008).
240. Lin SL, Chiang A, Chang D, Ying SY: Loss of mir-146a function in hormone-refractory prostate cancer. RNA 14(3), 417-424 (2008).
241. Yoon S, De Micheli G: Prediction of regulatory modules comprising microRNAs and target genes. Bioinformatics 21(Suppl. 2), II93-II100 (2005).
242. Bonci D, Coppola V, Musumeci M et al.: The miR-15a-miR-16-11 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 14(11), 1271-1277 (2008).
243. Prueitt RL, Yi M, Hudson RS et al.: Expression of microRNAs and protein-coding genes associated with perineural invasion in prostate cancer. Prostate 68(11), 1152-1164 (2008).
244. O'Donnell KA, Wentzel EA, Zeller KI, Dang CV, Mendell JT: c-Myc-regulated microRNAs modulate E2F1 expression. Nature 435(7043), 839-843 (2005).
245. Murakami Y, Yasuda T, Saigo K et al.: Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene 25(17), 2537-2545 (2006).
246. Chan JA, Krichevsky AM, Kosik KS: MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res. 65(14), 6029-6033 (2005).
247. Ciafre SA, Galardi S, Mangiola A et al.: Extensive modulation of a set of microRNAs in primary glioblastoma. Biochem. Biophys. Res. Commun. 334(4), 1351-1358 (2005).
248. Iorio MV, Ferracin M, Liu CG et al.: MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 65(16), 7065-7070 (2005).
249. Liu JY, Chuang TC, Way TD et al.: The N-terminal domain of EBNA1 acts as a suppressor of the HER2/neu oncogene. Cancer Lett. 273(2), 273-280 (2008).
250. Criswell TL, Dumont N, Barnett JV, Arteaga CL: Knockdown of the transforming growth factor-b type III receptor impairs motility and invasion of metastatic cancer cells. Cancer Res. 68(18), 7304-7312 (2008).
251. Yang J, Song K, Krebs TL, Jackson MW, Danielpour D: Rb/E2F4 and Smad2/3 link survivin to TGF-b-induced apoptosis and tumor progression. Oncogene 27(40), 5326-5338 (2008).
252. Barrack ER: TGF-b in prostate cancer: a growth inhibitor that can enhance tumorigenicity. Prostate 31(1), 61-70 (1997).
253. Jakowlew SB: Transforming growth factor-b in cancer and metastasis. Cancer Metastasis Rev. 25(3), 435-457 (2006).
254. Bello-DeOcampo D, Tindall DJ: TGF-bl/Smad signaling in prostate cancer. Curr. Drug Targets 4(3), 197-207 (2003).
255. Acquaviva J, Chen X, Ren R: IRF-4 functions as a tumor suppressor in early B-cell development. Blood 112(9), 3798-3806 (2008).
256. Wang Z, Smith KS, Murphy M et al.: Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy. Nature 455(7217), 1205-1209 (2008).
257. Chalhoub N, Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu. Rev. Pathol. 4, 127-150 (2009).
258. DeGraffenried LA, Fulcher L, Friedrichs WE et al.: Reduced PTEN expression in breast cancer cells confers susceptibility to inhibitors of the PI3 kinase/Akt pathway. Ann. Oncol. 15(10), 1510-1516 (2004).
259. Wong KK, Engelman JA, Cantley LC: Targeting the PI3K signaling pathway in cancer. Curr. Opin. Genet. Dev. 20(1), 87-90 (2009).
260. Sun X, Huang J, Homma T et al.: Genetic alterations in the PI3K pathway in prostate cancer. Anticancer Res. 29(5), 1739-1743 (2009).
261. Sarker D, Reid AH, Yap TA, de Bono JS: Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin. Cancer Res. 15(15), 4799-4805 (2009).
262. Morgan TM, Koreckij TD, Corey E: Targeted therapy for advanced prostate cancer: inhibition of the PI3K/Akt/mTOR pathway. Curr. Cancer Drug Targets 9(2), 237-249 (2009).
263. Chen M, Cassidy A, Gu J et al.: Genetic variations in PI3K-AKT-mTOR pathway and bladder cancer risk. Carcinogenesis 30(12), 2047-2052 (2009).
264. Yuan TL, Cantley LC: PI3K pathway alterations in cancer: variations on a theme. Oncogene 27(41), 5497-5510 (2008).
265. Georgescu MM: NHERF1: molecular brake on the PI3K pathway in breast cancer. Breast Cancer Res. 10(2), 106 (2008).
266. Cohen Y, Shalmon B, Korach J et al.: AKT1 pleckstrin homology domain E17K activating mutation in endometrial carcinoma. Gynecol. Oncol. 116(1), 88-91 (2010).
267. Askham JM, Platt F, Chambers PA et al.: AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K. Oncogene 29(1), 150-155 (2010).
268. Boormans JL, Hermans KG, van Leenders GJ, Trapman J, Verhagen PC: An activating mutation in AKT1 in human prostate cancer. Int. J. Cancer 123(11), 2725-2726 (2008).
269. Mohamedali A, Lea NC, Feakins RM et al.: AKT1E17K mutation in pancreatic cancer. Technol. Cancer Res. Treat. 7(5), 407-408 (2008).
270. Bleeker FE, Felicioni L, Buttitta F et al.: AKT1E17K in human solid tumours. Oncogene 27, 5648-5650 (2008).
271. Zupnick A, Prives C: Mutational analysis of the p53 core domain L1 loop. J. Biol. Chem. 281(29), 20464-20473 (2006)